AcelRx, Gruenenthal, PDL BioPharma deal

AcelRx sold to PDL a portion of the royalties and milestone payments related to pain product Zalviso sufentanil in the EU, Switzerland and Australia. AcelRx will receive $65 million in exchange for 75% of the royalties and 80% of the first four commercialization milestone payments it receives from Gruenenthal. In 2013, AcelRx granted Gruenenthal commercialization rights in Europe and Australia to Zalviso in exchange for $30 million up front and up to $220 million in milestones, plus royalties. ...